WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563562

CAS#: 308818-13-5

Description: ALS-1 is an acid-Liable surfactant.

Chemical Structure

CAS# 308818-13-5

Theoretical Analysis

MedKoo Cat#: 563562
Name: ALS-1
CAS#: 308818-13-5
Chemical Formula: C19H37NaO6S
Exact Mass: 416.2209
Molecular Weight: 416.54
Elemental Analysis: C, 54.79; H, 8.95; Na, 5.52; O, 23.05; S, 7.70

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ALS-1; ALS 1; ALS1; Acid-Liable Surfactant-1;

IUPAC/Chemical Name: Sodium 3-[(2-methyl-2-undecyl-1,3-dioxolan-4-yl)methoxy]-1-propanesulfonate


InChi Code: InChI=1S/C19H38O6S.Na/c1-3-4-5-6-7-8-9-10-11-13-19(2)24-17-18(25-19)16-23-14-12-15-26(20,21)22;/h18H,3-17H2,1-2H3,(H,20,21,22);/q;+1/p-1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 416.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, Körner S, Ringer TM, Rödiger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chiò A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018 May;17(5):423-433. doi: 10.1016/S1474-4422(18)30089-9. Epub 2018 Mar 26. PubMed PMID: 29598923.

2: Lambert C, Cubedo J, Padró T, Vilahur G, López-Bernal S, Rocha M, Hernández-Mijares A, Badimon L. Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism. Nutrients. 2018 Feb 27;10(3). pii: E271. doi: 10.3390/nu10030271. PubMed PMID: 29495516; PubMed Central PMCID: PMC5872689.

3: Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018 Mar;265(3):510-521. doi: 10.1007/s00415-017-8730-6. Epub 2018 Jan 10. PubMed PMID: 29322259.

4: Bingham BA, Duong MT, Ricks M, Mabundo LS, Baker RL Jr, Utumatwishima JN, Udahogora M, Berrigan D, Sumner AE. The Association between Stress Measured by Allostatic Load Score and Physiologic Dysregulation in African Immigrants: The Africans in America Study. Front Public Health. 2016 Nov 25;4:265. eCollection 2016. PubMed PMID: 27933289; PubMed Central PMCID: PMC5122568.

5: Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Philtjens S, Heeman B, Engelborghs S, Vandenbulcke M, De Baets G, Bäumer V, Cuijt I, Van den Broeck M, Peeters K, Mattheijssens M, Rousseau F, Vandenberghe R, De Jonghe P, Cras P, De Deyn PP, Martin JJ, Cruts M, Van Broeckhoven C; BELNEU Consortium. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology. 2015 Dec 15;85(24):2116-25. doi: 10.1212/WNL.0000000000002220. Epub 2015 Nov 18. PubMed PMID: 26581300; PubMed Central PMCID: PMC4691687.

6: Sanghavi P, Jena AB, Newhouse JP, Zaslavsky AM. Outcomes of Basic Versus Advanced Life Support for Out-of-Hospital Medical Emergencies. Ann Intern Med. 2015 Nov 3;163(9):681-90. doi: 10.7326/M15-0557. Epub 2015 Oct 13. PubMed PMID: 26457627; PubMed Central PMCID: PMC4945100.

7: Geevasinga N, Menon P, Nicholson GA, Ng K, Howells J, Kril JJ, Yiannikas C, Kiernan MC, Vucic S. Cortical Function in Asymptomatic Carriers and Patients With C9orf72 Amyotrophic Lateral Sclerosis. JAMA Neurol. 2015 Nov;72(11):1268-74. doi: 10.1001/jamaneurol.2015.1872. PubMed PMID: 26348842; PubMed Central PMCID: PMC4707047.

8: Cheskes S, Hillier M, Byers A, Verbeek PR, Drennan IR, Zhan C, Morrison LJ. The association between manual mode defibrillation, pre-shock pause duration and appropriate shock delivery when employed by basic life support paramedics during out-of-hospital cardiac arrest. Resuscitation. 2015 May;90:61-6. doi: 10.1016/j.resuscitation.2015.02.022. Epub 2015 Feb 28. PubMed PMID: 25737080.

9: Qiao L, Li X, Liu M, Cui L. [Nature history of amyotrophic lateral sclerosis]. Zhonghua Yi Xue Za Zhi. 2014 Mar 11;94(9):674-7. Chinese. PubMed PMID: 24842207.

10: Bucheli ME, Calderón A, Chicaiza D, Franco C, López R, Digga E, Atassi N, Salameh J, Berry JD. Feedback interaction of research, advocacy, and clinical care applied to ALS research in South America. Neurology. 2013 Nov 26;81(22):1959-61. doi: 10.1212/01.wnl.0000436610.28210.a5. PubMed PMID: 24276333; PubMed Central PMCID: PMC3843379.

11: Dimachkie MM, Muzyka IM, Katz JS, Jackson C, Wang Y, McVey AL, Dick A, Pasnoor M, Mozaffar MT, Xiao-Song Z, Kissel JT, Ensrud E, Rosenfeld J, Barohn RJ. Leg amyotrophic diplegia: prevalence and pattern of weakness at US neuromuscular centers. J Clin Neuromuscul Dis. 2013 Sep;15(1):7-12. doi: 10.1097/CND.0b013e31829e22d1. PubMed PMID: 23965403; PubMed Central PMCID: PMC4005892.

12: Menon P, Bae JS, Mioshi E, Kiernan MC, Vucic S. Split-hand plus sign in ALS: differential involvement of the flexor pollicis longus and intrinsic hand muscles. Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):315-8. doi: 10.3109/21678421.2012.734521. Epub 2012 Oct 22. PubMed PMID: 23121291.

13: Ogino M. [Survey report on end-of-life care for ALS patients of ALS physicians in Japan]. Rinsho Shinkeigaku. 2010 Nov;50(11):1026-8. Japanese. PubMed PMID: 21921553.

14: López Gómez JJ, Ballesteros Pomar MD, Vázquez Sánchez F, Vidal Casariego A, Calleja Fernández A, Cano Rodríguez I. [Effect of nutritional support on survival in patients with amyotrophic lateral sclerosis]. Nutr Hosp. 2011 May-Jun;26(3):515-21. doi: 10.1590/S0212-16112011000300013. Spanish. PubMed PMID: 21892569.

15: van Groenestijn AC, van de Port IG, Schröder CD, Post MW, Grupstra HF, Kruitwagen ET, van der Linde H, van Vliet RO, van de Weerd MG, van den Berg LH, Lindeman E. Effects of aerobic exercise therapy and cognitive behavioural therapy on functioning and quality of life in amyotrophic lateral sclerosis: protocol of the FACTS-2-ALS trial. BMC Neurol. 2011 Jun 14;11:70. doi: 10.1186/1471-2377-11-70. PubMed PMID: 21672211; PubMed Central PMCID: PMC3125309.

16: Prieto R, Pascual JM, Gutiérrez R, Santos E. Recovery from paraplegia after the treatment of spinal dural arteriovenous fistula: case report and review of the literature. Acta Neurochir (Wien). 2009 Nov;151(11):1385-97. doi: 10.1007/s00701-009-0439-6. Epub 2009 Jul 18. Review. PubMed PMID: 19618103.

17: Baragi VM, Becher G, Bendele AM, Biesinger R, Bluhm H, Boer J, Deng H, Dodd R, Essers M, Feuerstein T, Gallagher BM Jr, Gege C, Hochgürtel M, Hofmann M, Jaworski A, Jin L, Kiely A, Korniski B, Kroth H, Nix D, Nolte B, Piecha D, Powers TS, Richter F, Schneider M, Steeneck C, Sucholeiki I, Taveras A, Timmermann A, Van Veldhuizen J, Weik J, Wu X, Xia B. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum. 2009 Jul;60(7):2008-18. doi: 10.1002/art.24629. PubMed PMID: 19565489.

18: Recchia F, Candeloro G, Di Staso M, Necozione S, Bisegna R, Bratta M, Tombolini V, Rea S. Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck. J Immunother. 2008 May;31(4):413-9. doi: 10.1097/CJI.0b013e31816d1d8e. PubMed PMID: 18391754.

19: Recchia F, Candeloro G, Necozione S, Fumagalli L, Bratta M, Rea S. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma. Anticancer Drugs. 2008 Feb;19(2):201-7. doi: 10.1097/CAD.0b013e3282f2c0bc. PubMed PMID: 18176117.

20: Beghi E, Millul A, Micheli A, Vitelli E, Logroscino G; SLALOM Group. Incidence of ALS in Lombardy, Italy. Neurology. 2007 Jan 9;68(2):141-5. PubMed PMID: 17210896.